- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic colorectal cancer
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 360KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 89KB)
Cetuximab – March 2024
Cetuximab: Solution for I.V. infusion 100 mg in 20 mL, Solution for I.V. infusion 500 mg in 100 mL; Erbitux®
Last updated
30 May 2025